

FOSUN PHARMA
复星医药

2023



1

2

3

4

5

6



2023

1/2





Ⓢ PD-1

1H23 5.56

3 ES-SCLC

ES-SCLC

PD-1

3 ES-SCLC

MAA EMA

9 ESCC



Argesun®



Ⓢ

#



Ⓢ

#



Ⓢ

#



Ⓢ

#



Ⓢ



Ⓢ



Ⓢ



Ⓢ HER2

RT002

#

Tenapanor

#

FS-1502 HER2-ADC #



13

FCN-159 MEK

ET-26



SAB Scientific Advisory Board






CDE 2021 7



DRG/DIP



药友制药 | FOSUN PHARMA
 万邦医药 | FOSUN PHARMA
 麒麟南药 | FOSUN PHARMA



Alma

FOSUN IDGENVAX
复星安特金

cenexi
 creating innovative partnerships
 Gland Pharma
 2023 4
 CDMO Cenexi



mRNA





/ADC RNA




02




01

03













MSCI-ESG A






-


1



2,3




3



SCLC PD-1



PD-1



(ASTCT)

r/r LBCL

2023 6 r/r LBCL

CAR-T

B LBCL
1.3

LBCL NHL 45.8%

NHL LBCL 4

ZUMA-1

RWS

ZUMA-7

bORR

bCR

OS

500

2023 6

140

25

10,000

GMP

2023 6

60

90

FL

MZL

2021 8

r/r FL

Kite Pharma

CAR-T
/








Tecartus
B

2020 7

FDA
r/r ALL

/

MCL










-

1


1,2

1







1H23 /



BeautiFill
LipoSense
CellFie





Ion

1H23
1,100

2000
FDA
8,042


2023 6
55,000
1,000

34
330






1




2011-2017

2,3



2018-2020

3



2021

6,448 * 9

JCI


1H23

" "



600

2017 11 9.09
60%



800

1,750

2022

21.45


1.11

900

87.41%

2022 1

70%



*

2023 6



406,382

445,920




3Q22

3Q23






5,857















2,254





		®		
		®		
		®		
		®		
		®*		

		®*		
		®*		
		®*		
	T	®*		
		®		
		®		

		®*		
		®*		
				
		®*		
		mRNA ®*		
				

1/2

			/		IND	1	2	3	NDA
HLX10 ¹	+		PD-1	/	III 2022 11				
					2022 11	2022 FDA/EC	2023 1		
	+ +		PD-1		III 2023 1	2022 5			
	+		PD-1+VEGF						
	+HLX07		PD-1+EGFR						
	+HLX07 +		PD-1+EGFR +VEGF		2022 1				
HLX07		EGFR							
HLX22									
HLX11	2		HER2		III 2022				
HLX05	3		EGFR						
HLX02	4		HER2		FDA 2020				

1 KG Bio 10
3
5 2023 10 31

2 Organon
4 Accord Cipla Jacobson mAbxience Eurofarma Abbott



1/2

		/		IND	1	2	3	NDA
FCN-437c		CDK4/6	1L					
			2L					
SAF-189		ALK/ROS1	ALK+	2022 1 NMPA				III
			ROS1+					
HLX-208	-	BRAF	Erdheim-Chester ECD LCH	2023 4 LCH ECD NMPA				
		BRAF+PD-1	BRAF V600E BRAF V600					
FCN-159		MEK	I	2023 7 NMPA			II	
				2023 4 NMPA	2022 5 NMPA			
YP01001		VEGFR		NMPA				
FCN-338		BCL-2		NMPA				
			B					
FH-2001		FGFR/PD-L1						
ORIN1001		IRE1						

2/2

	/		IND	1	2	3	NDA
	TPO-R	ITP					
Tenapanor	NHE 3	(ESRD-HD)					
	P-CAB		I				
Tenapanor	NHE 3	(IBS-C)	I				
PA-824	-	XDR-TB / MDR-TB	Pretomanid*				
Opicapone	COMT		Ongentys*				
Fortacin	-		-				
ET-26	-		2023 10	III			
FCN-159	MEK						
ORIN1001	IRE1		I				
FCN-016	ROCK		2023 1	NMPA			
SZEY-2108	-	CRE	2023 6	NMPA			

			IND	1	2	3	NDA
	/						
	/						
	/						
13							
24							
23							
	-						

2023 10 31

LOGO

Fosun Pharma, the Representor or the Provider will not warrant the accuracy, the completeness and the timeliness of all information and contents, including predictive description, contained in the PPT documents/visual materials. In the event of any mistake, omission, and inaccuracy, Fosun Pharma, the Representor or the Provider should not be held for any liabilities in this regard.

The PPT documents/visual materials will not include and should not be deemed as any investment proposals. The investor should take their own responsibilities for any determinations so come to based upon the information contained in the PPT documents/visual materials.

Fosun Pharma is entitled to all rights, including copyright, pertaining to the PPT documents/visual materials. The characters, the designs and Fosun , are the trade name, trademark and the logos legally owned by Fosun Pharma. Without written consent offered by Fosun Pharma, any third party should not utilize such materials and information in any manner, including reprinting.



www.fosunpharma.com